Manual Das Denominações Comuns Brasileiras

Total Page:16

File Type:pdf, Size:1020Kb

Manual Das Denominações Comuns Brasileiras MDCB Manual das Denominações Comuns Brasileiras Organizadores Lauro D. Moretto Volume Rosana Mastelaro 16 2013 MDCB Manual das Denominações Comuns Brasileiras Organizadores Lauro D. Moretto Volume Rosana Mastelaro 16 2013 Dados Internacionais de Catalogação na Publicação (CIP) (Câmara Brasileira do Livro, SP, Brasil) MDCB : Manual das Denominações Comuns Brasileiras / coordenadores Lauro D. Moretto, Rosana Mastelaro. -- São Paulo : SINDUSFARMA, 2013. -- (Manuais SINDUSFARMA ; v. 16) 1. Medicamentos - Brasil - Nomenclatura I. Moretto, Lauro D.. II. Mastelaro, Rosana. III. Série. CDD-615.1014 13-03273 NLM-QV-704 Índices para catálogo sistemático: 1. DCB : Denominações Comuns Brasileiras : Ciências farmacêuticas 615.1014 2. Fármacos ou medicamentos : Denominações Comuns Brasileiras : Nomenclatura : Ciências farmacêuticas 615.1014 3. fármacos ou medicamentos : denominações comuns brasileiras : Nomenclatura : Ciências farmacêuticas QV-704 Copyright 2013 Agência Nacional de Vigilância Sanitária Todos os direitos reservados. É permitida a reprodução parcial ou total desta obra, desde que citada a fonte. Manual das Denominações Comuns Brasileiras O SINDUSFARMA – Sindicato da Indústria de Produtos Farmacêuticos no Estado de São Paulo elaborou este livro, MDCB – Manual das Denominações Comuns Brasileiras, em conjunto com a ANVISA contendo, na íntegra, os textos das Resoluções RDC n° 63, de 28 de dezembro de 2012 e RDC nº 64, de 28 de dezembro de 2012 que, respectivamente, definem os critérios de nomenclatura e a relação atualizada das Denominações Comuns Brasileiras vigentes. Este compêndio tem por escopo facilitar a consulta e utilização das DCBs, em complemento à versão eletrônica disponibilizada pela ANVISA. Com isso o SINDUSFARMA, coerente com a sua política de prover atualização dos temas técnico-regulatórios, edita este manual e o coloca à disposição dos profissionais do quadro associativo e do corpo de funcionários da ANVISA que atuam em áreas farmacêuticas. Esta iniciativa do SINDUSFARMA, acordada com a Diretoria Colegiada da ANVISA, vem reforçar o objetivo destas instituições na organização e divulgação da regulamentação pertinente ao setor industrial farmacêutico. O livro MDCB representa mais uma importante contribuição do SINDUSFARMA aos seus associados, que se incorpora e amplia sua coletânea técnico-regulatória. São Paulo, maio de 2013. Nelson A. Mussolini Lauro D. Moretto Presidente Executivo Vice Presidente Executivo 3 Sindusfarma Presidente da República Dilma Vana Rousseff Ministro de Estado da Saúde Alexandre Rocha Santos Padilha Diretor-Presidente Dirceu Brás Aparecido Barbano Diretores Jaime César de Moura Oliveira José Agenor Álvares da Silva Adjuntos de Diretores Luiz Roberto da Silva Klassmann Neilton Araujo de Oliveira Luciana Shimizu Takara Presidente da Farmacopeia Brasileira Gerson Antônio Pianetti Coordenação da Farmacopeia Brasileira - COFAR Mônica da Luz Carvalho Soares - Coordenadora Andrea Rezende Oliveira Jaimara Azevedo Oliveira Silvânia Vaz de Melo Mattos Luana Martins da Luz – Secretária Washington Ferreira - Secretário Brasil. Manual das Denominações Comuns Brasileiras - DCB, Agência Nacional de Vigilância Sanitária. Brasília: Anvisa, 2013 Elaboração e edição: Agência Nacional de Vigilância Sanitária SIA Trecho 5, Área Especial 57, Lote 200 71205-050 Brasília – DF Tel.: +55 (61) 3462-4123 Home page: http://www.anvisa.gov.br/farmacopeiabrasileira/index.htm 4 Manual das Denominações Comuns Brasileiras SUMÁRIO Prefácio ................................................................................................7 Histórico...............................................................................................8 Apresentação ...................................................................................... 11 Comissão da Farmacopeia Brasileira - CFB .............................................. 13 Comitês técnicos temáticos da Comissão da Farmacopeia Brasileira relacionados com esta edição do MDCB .................................................. 15 Colaboradores das listas de DCB ............................................................ 19 Definições .......................................................................................... 20 Abreviaturas ....................................................................................... 22 A. REGRAS DE NOMENCLATURA DAS DCB, TRADUÇÃO DE NOMES E ABREVIATURA DE GRUPOS QUÍMICOS RESOLUÇÃO DA DIRETORIA COLEGIADA – RDC N° 63, DE 28 DE DEZEMBRO DE 2012. .................................................................. 23 CAPÍTULO I DAS DISPOSIÇÕES INICIAIS ....................................................... 23 CAPÍTULO II DAS DISPOSIÇÕES GERAIS ......................................................... 23 CAPÍTULO III DAS REGRAS DE NOMENCLATURA DE DCB ..................................... 24 Seção I - Dos Fundamentos Gerais .................................................... 24 Seção II - Dos Fundamentos Específicos ............................................ 25 Subseção I - Dos Insumos Farmacêuticos ..................................... 25 Subseção II - Dos soros hiperimunes heterólogos e vacinas ............ 27 Subseção III - Dos Radiofármacos ............................................... 30 Subseção IV - Das Plantas Medicinais ........................................... 30 Subseção V - Das Substâncias Homeopáticas ................................ 30 Seção III - Das Regras para a Tradução de Nomes de Insumos do Inglês para o Português e de Utilização de Radicais e Abreviaturas de Grupos Químicos ....................................................................................... 31 CAPÍTULO IV DA OFICIALIZAÇÃO DAS DCB ...................................................... 31 CAPÍTULO V DAS DISPOSIÇÕES FINAIS E TRANSITÓRIAS ................................. 32 INSTRUÇÃO NORMATIVA N° 5, DE 28 DE DEZEMBRO DE 2012 - Dispõe sobre os procedimentos para solicitar a inclusão, alteração ou exclusão de Denominações Comuns Brasileiras – DCB ............................................... 33 ANEXOS ............................................................................................. 36 Anexo 1 Identificadores das referências bibliográficas utilizadas na definição das DCB ..... 37 5 Sindusfarma Anexo 2 Regras para a tradução de nomes de insumos do inglês para o português ... 38 Anexo 3 Regras de utilização de Radicais e Abreviaturas de Grupos Químicos ........... 43 A.3.1 Relação de Radicais (prefixo, infixo e sufixo) de Grupos Químicos .. 43 A.3.2 Abreviatura de Grupos Químicos ............................................... 56 Anexo 4 - MODELO DE FORMULÁRIO ...................................................... 61 A.4.1 MODELO DO FORMULÁRIO PARA SOLICITAÇÃO DE DCB (ANEXO I DA IN Nº 5/1012) ...................................................................... 61 A.4.2 INSTRUÇÕES PARA O PREENCHIMENTO DO FORMULÁRIO PARA SOLICITAÇÃO, ALTERAÇÃO E EXCLUSÃO DE DCB............................ 62 ANEXO 5 - LISTAS DAS DCB ................................................................. 65 INSUMOS FARMACÊUTICOS INDEXAÇÃO POR NOME ............................................................... 65 INSUMOS FARMACÊUTICOS INDEXAÇÃO POR NÚMERO DCB .................................................. 217 BIOLÓGICOS INDEXAÇÃO POR NOME ............................................................. 368 BIOLÓGICOS INDEXAÇÃO POR NÚMERO DCB .................................................. 372 RADIOFÁRMACOS INDEXAÇÃO POR NOME ............................................................. 377 RADIOFÁRMACOS INDEXAÇÃO POR NÚMERO DCB .................................................. 382 PLANTAS MEDICINAIS INDEXAÇÃO POR NOME ............................................................. 387 PLANTAS MEDICINAIS INDEXAÇÃO POR NÚMERO DCB .................................................. 391 SUBSTÂNCIAS HOMEOPÁTICAS INDEXAÇÃO POR NOME ............................................................. 395 SUBSTÂNCIAS HOMEOPÁTICAS INDEXAÇÃO POR NÚMERO DCB .................................................. 404 LISTA INDENTADA CLASSIFICAÇÃO PELAS BASES QUÍMICAS E BIOLÓGICAS .............. 413 6 Manual das Denominações Comuns Brasileiras PREFÁCIO A atual Comissão da Farmacopeia Brasileira – CFB – teve como meta entregar à sociedade as versões revisadas da Farmacopeia Brasileira e seus componentes. Foram, então, aprovados pela Agência Nacional de Vigilância Sanitária – ANVISA – a quinta edição da Farmacopeia Brasileira, a terceira edição da Farmacopeia Homeopática Brasileira, o Formulário Fitoterápico da Farmacopeia Brasileira, a segunda edição do Formulário Nacional da Farmacopeia Brasileira, as substâncias químicas de referência e o Manual de Redação de Monografias. O Manual das Denominações Comuns Brasileiras – MDCB encerra o ciclo dos componentes e cumpre o importante papel de ser o documento oficial para o estabelecimento e a padronização de regras de nomenclatura e tradução de termos relacionados a substâncias de interesse farmacêutico, empregadas em processos e materiais de divulgação, didático, técnico e científico no País. As DCB são fundamentais para dar suporte à política nacional de medicamentos genéricos e garantir a sua utilização em áreas de registro de medicamentos na Anvisa, em licitações, em manipulação de medicamentos, no rastreamento de insumos, na prescrição médica, em legislações e em qualquer outra forma de pesquisa científica ou de trabalho na qual venha a ser útil. A atual lista elenca 10.780 denominações genéricas, de domínio público, visando
Recommended publications
  • Liothyronine Sodium(BANM, Rinnm) Potassium Perchlorate
    2174 Thyroid and Antithyroid Drugs with methodological limitations. However, a controlled trial of In myxoedema coma liothyronine sodium may be liothyronine with paroxetine could not confirm any advantage of given intravenously in a dose of 5 to 20 micrograms by 3 O additive therapy. slow intravenous injection, repeated as necessary, usu- 1. Aronson R, et al. Triiodothyronine augmentation in the treat- HO I ally at intervals of 12 hours; the minimum interval be- ment of refractory depression: a meta-analysis. Arch Gen Psychi- OH atry 1996; 53: 842–8. tween doses is 4 hours. An alternative regimen advo- 2. Altshuler LL, et al. Does thyroid supplementation accelerate tri- NH2 cates an initial dose of 50 micrograms intravenously cyclic antidepressant response? A review and meta-analysis of I O the literature. Am J Psychiatry 2001; 158: 1617–22. followed by further injections of 25 micrograms every 3. Appelhof BC, et al. Triiodothyronine addition to paroxetine in I 8 hours until improvement occurs; the dosage may the treatment of major depressive disorder. J Clin Endocrinol then be reduced to 25 micrograms intravenously twice Metab 2004; 89: 6271–6. (liothyronine) daily. Obesity. Thyroid drugs have been tried in the treatment of obes- Liothyronine has also been given in the diagnosis of ity (p.2149) in euthyroid patients, but they produce only tempo- NOTE. The abbreviation T3 is often used for endogenous tri-io- hyperthyroidism in adults. Failure to suppress the up- rary weight loss, mainly of lean body-mass, and can produce se- dothyronine in medical and biochemical reports. Liotrix is USAN rious adverse effects, especially cardiac complications.1 for a mixture of liothyronine sodium with levothyroxine sodium.
    [Show full text]
  • Common Thyroid Disorders
    9/7/17 Common Louie Riesch MSN, MPH, RN, ACNS-BC, CDE Thyroid Texas Diabetes and Endocrinology Disorders Anatomy of the Thyroid Gland Hypothalamic-Pituitary-Thyroid Axis Physiology Hypothalamus TRH • TSH reflects tissue thyroid – hormone actions • TSH as an index of Pituitary therapeutic success and – potential toxicity TSH T4 Target Tissues T3 Heart Thyroid Gland Liver T4 T3 TR Bone T4 è T3 Liver CNS 1 9/7/17 Production of T4 and T3 Ê T4 is the primary secretory product of the thyroid gland, which is the only source of T4 Ê The thyroid secretes approximately 100 nmol of T4 per day Ê T3 is derived from 2 processes Ê The total daily production rate of T3 is about 15-30 µg Ê About 80% of circulating T3 comes from deiodination of T4 in peripheral tissues Ê Largely liver and kidneys Ê About 20% comes from direct thyroid secretion Free Hormone Concept Ê Only unbound (free) hormone has metabolic activity and physiologic effects Ê Total hormone concentration Ê Normally is kept proportional to the concentration of carrier proteins Ê Is kept appropriate to maintain a constant free hormone level 2 9/7/17 Drugs and Conditions That Increase Serum T4 and T3 Levels by Increasing TBG Drugs that increase TBG Conditions that increase TBG Ê Oral contraceptives and other Ê Pregnancy sources of estrogen Ê Infectious/chronic active Ê Methadone hepatitis Ê Clofibrate Ê HIV infection Ê 5-Fluorouracil Ê Biliary cirrhosis Ê Heroin Ê Acute intermittent porphyria Ê Tamoxifen Ê Genetic factors Evaluate for thyroid disease Ê All >35 years of age, every 5 years Ê
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • Trabajo De Diploma
    Facultad de Química-Farmacia Departamento de Farmacia Trabajo de diploma Título: Evaluación experimental “in vivo” de nuevos compuestos con actividad analgésica seleccionados a través del tamizaje virtual. Autor: Yulier León Mederos Tutores: Dr. Yovani Marrero Ponce MSc. Arelis López Sacerio 2009-2010 Exergo Todos y cada uno de nosotros paga puntualmente su cuota de sacrificio consciente de recibir el premio en la satisfacción del deber cumplido, conscientes de avanzar con todos hacia el Hombre Nuevo que se vislumbra en el horizonte... Che Yulier León Mederos Evaluación experimental “in vivo” de nuevos compuestos con actividad analgésica seleccionados a través del tamizaje virtual Dedicatoria A alguien que se lo merece, por su ayuda y su apoyo durante esta larga carrera como estudiante universitario, mi madre la cual confió siempre en mí y por ver esperado con paciencia esta gran hazaña. Elisa Jorge por verse convertido en mi madre y por su apoyo incondicional cada día que transcurrió en esta escuela. A mis hermanos por estar siempre a mí lado cuando más yo los necesitaba, a mi abuela que no pudo disfrutar esta gran victoria junto a mí, pero allá donde ella está le llegará este lindo regalo. Yulier León Mederos Evaluación experimental “in vivo” de nuevos compuestos con actividad analgésica seleccionados a través del tamizaje virtual Agradecimientos Esta página está dedicada a todas aquellas personas que de un modo u otro hicieron posible la realización de esta tesis. Quisiera agradecer en primer lugar a mi madre que siempre depositó todo su amor y confianza en mí, sobre todo en los momentos difíciles a lo largo de mi carrera A mis hermanos ya que sus consejos siempre fueron buenos y por el aprecio que siento hacia ellos.
    [Show full text]
  • Liothyronine Sodium(BANM, Rinnm) Potassium Perchlorate
    2174 Thyroid and Antithyroid Drugs with methodological limitations. However, a controlled trial of In myxoedema coma liothyronine sodium may be liothyronine with paroxetine could not confirm any advantage of given intravenously in a dose of 5 to 20 micrograms by 3 O additive therapy. slow intravenous injection, repeated as necessary, usu- 1. Aronson R, et al. Triiodothyronine augmentation in the treat- HO I ally at intervals of 12 hours; the minimum interval be- ment of refractory depression: a meta-analysis. Arch Gen Psychi- OH atry 1996; 53: 842–8. tween doses is 4 hours. An alternative regimen advo- 2. Altshuler LL, et al. Does thyroid supplementation accelerate tri- NH2 cates an initial dose of 50 micrograms intravenously cyclic antidepressant response? A review and meta-analysis of I O the literature. Am J Psychiatry 2001; 158: 1617–22. followed by further injections of 25 micrograms every 3. Appelhof BC, et al. Triiodothyronine addition to paroxetine in I 8 hours until improvement occurs; the dosage may the treatment of major depressive disorder. J Clin Endocrinol then be reduced to 25 micrograms intravenously twice Metab 2004; 89: 6271–6. (liothyronine) daily. Obesity. Thyroid drugs have been tried in the treatment of obes- Liothyronine has also been given in the diagnosis of ity (p.2149) in euthyroid patients, but they produce only tempo- NOTE. The abbreviation T3 is often used for endogenous tri-io- hyperthyroidism in adults. Failure to suppress the up- rary weight loss, mainly of lean body-mass, and can produce se- dothyronine in medical and biochemical reports. Liotrix is USAN rious adverse effects, especially cardiac complications.1 for a mixture of liothyronine sodium with levothyroxine sodium.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 7,795,310 B2 Lee Et Al
    US00779531 OB2 (12) United States Patent (10) Patent No.: US 7,795,310 B2 Lee et al. (45) Date of Patent: Sep. 14, 2010 (54) METHODS AND REAGENTS FOR THE WO WO 2005/025673 3, 2005 TREATMENT OF METABOLIC DISORDERS OTHER PUBLICATIONS (75) Inventors: Margaret S. Lee, Middleton, MA (US); Tenenbaum et al., “Peroxisome Proliferator-Activated Receptor Grant R. Zimmermann, Somerville, Ligand Bezafibrate for Prevention of Type 2 Diabetes Mellitus in MA (US); Alyce L. Finelli, Patients With Coronary Artery Disease'. Circulation, 2004, pp. 2197 Framingham, MA (US); Daniel Grau, 22O2.* Shen et al., “Effect of gemfibrozil treatment in sulfonylurea-treated Cambridge, MA (US); Curtis Keith, patients with noninsulin-dependent diabetes mellitus'. The Journal Boston, MA (US); M. James Nichols, of Clinical Endocrinology & Metabolism, vol. 73, pp. 503-510, Boston, MA (US) 1991 (see enclosed abstract).* International Search Report from PCT/US2005/023030, mailed Dec. (73) Assignee: CombinatoRx, Inc., Cambridge, MA 1, 2005. (US) Lin et al., “Effect of Experimental Diabetes on Elimination Kinetics of Diflunisal in Rats.” Drug Metab. Dispos. 17:147-152 (1989). (*) Notice: Subject to any disclaimer, the term of this Abstract only. patent is extended or adjusted under 35 Neogi et al., “Synthesis and Structure-Activity Relationship Studies U.S.C. 154(b) by 0 days. of Cinnamic Acid-Based Novel Thiazolidinedione Antihyperglycemic Agents.” Bioorg. Med. Chem. 11:4059-4067 (21) Appl. No.: 11/171,566 (2003). Vessby et al., “Effects of Bezafibrate on the Serum Lipoprotein Lipid and Apollipoprotein Composition, Lipoprotein Triglyceride Removal (22) Filed: Jun. 30, 2005 Capacity and the Fatty Acid Composition of the Plasma Lipid Esters.” Atherosclerosis 37:257-269 (1980).
    [Show full text]
  • Hyper and Hypothyroidism
    Editing File Mnemonic File Endocrine Block Pharmacology team 438 Hyper and Hypothyroidism Objectives: By the end of the lecture , you should know: ● Describe different classes of drugs used in hyperthyroidism and hypothyroidism and their mechanism of action ● Understand their pharmacological effects, clinical uses and adverse effects ● Recognize treatment of special cases such as hyperthyroidism during pregnancy, Graves’ disease and Thyroid Storm and special cases of hypothyroidism such as myxedema coma Color index: Black : Main content Purple: Females’ slides only Red : Important Grey: Extra info or explanation Blue: Males’ slides only Green : Dr. notes Hyperthyroidism Thyroid Function ● Normal amount of thyroid hormones are essential for normal growth and development by maintaining the level of energy metabolism in the tissue. ● Either too little or too much thyroid hormones will bring disorders to the body. Important Functions CVS: increase Growth & Thermoregulation Helps maintain heart rate & development, increase basal metabolic cardiac output especially in the metabolic rate energy balance which increase embryo & brain (BMR) oxygen demand Iodine Importance ● Thyroid hormones are unique biological molecules in that they incorporate iodine1 in their structure ● Adequate iodine intake (diet, water) is required for normal thyroid hormone production ● Major sources of iodine are: iodized salt, iodated bread, dairy products, shellfish ● Minimum requirement: 75 micrograms/day Iodine Metabolism 1 2 3 Iodide taken up by the Dietary iodine
    [Show full text]
  • Thyroid Disorders: a Multi-Disciplined Analysis
    Thyroid Disorders: A Multi-Disciplined Analysis Author: Chadwick J. Szylvian Persistent link: http://hdl.handle.net/2345/695 This work is posted on eScholarship@BC, Boston College University Libraries. Boston College Electronic Thesis or Dissertation, 2009 Copyright is held by the author, with all rights reserved, unless otherwise noted. Thyroid Disorders: A Multi-Disciplined Analysis Chadwick Szylvian Advised by Dr. John Wing, Ph. D. Boston College, Biology Department Cover image: “Echography of the thyroid gland”. Courtesy of CARRAT Medical Laboratory Tests Thyroid Disorders: A Multi-Disciplined Analysis Authored by Chadwick Szylvian, Boston College 2009 Introduction 3 I. The Endocrine System and the Thyroid Function 5 The Thyroid 6 II. Physiology The Endocrine System 8 The Thyroid and Coordinated Organs 8 Hyperthyroidism 10 Hypothyroidism 12 Human Development 14 III. Molecular Analysis Hormonal Analysis 19 Cellular Receptors of Thyroid Hormones 19 Non-Receptor, Molecular and Genetic Defects Leading to Thyroid Disorders 23 IV. Clinical Considerations – Testing, Pharmacology, and Systemic Integration Testing 26 Pharmacology 29 Thyroid Disorders and the Pharmaceutical Industry 32 Systemic Ramifications of Abnormal Thyroid Functioning 35 Advancing Treatments 37 Dietary Supplements and Thyroid Disorders 38 V. Closing Author Commentary 39 VI. Figures and Diagrams 40 VII. References 46 2 Introduction Despite weighing barely more than an ounce, the tiny butterfly-shaped thyroid gland is a vital metabolic regulator of the endocrine system. The body depends on this tissue of thyroid cells to produce a unique set of hormone products that perfuse throughout the body to maintain homeostatic metabolic function; the importance of this unassuming collection of cells cannot be underestimated.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr
    US008158152B2 (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr. 17, 2012 (54) LYOPHILIZATION PROCESS AND 6,884,422 B1 4/2005 Liu et al. PRODUCTS OBTANED THEREBY 6,900, 184 B2 5/2005 Cohen et al. 2002fOO 10357 A1 1/2002 Stogniew etal. 2002/009 1270 A1 7, 2002 Wu et al. (75) Inventor: Nageswara R. Palepu. Mill Creek, WA 2002/0143038 A1 10/2002 Bandyopadhyay et al. (US) 2002fO155097 A1 10, 2002 Te 2003, OO68416 A1 4/2003 Burgess et al. 2003/0077321 A1 4/2003 Kiel et al. (73) Assignee: SciDose LLC, Amherst, MA (US) 2003, OO82236 A1 5/2003 Mathiowitz et al. 2003/0096378 A1 5/2003 Qiu et al. (*) Notice: Subject to any disclaimer, the term of this 2003/OO96797 A1 5/2003 Stogniew et al. patent is extended or adjusted under 35 2003.01.1331.6 A1 6/2003 Kaisheva et al. U.S.C. 154(b) by 1560 days. 2003. O191157 A1 10, 2003 Doen 2003/0202978 A1 10, 2003 Maa et al. 2003/0211042 A1 11/2003 Evans (21) Appl. No.: 11/282,507 2003/0229027 A1 12/2003 Eissens et al. 2004.0005351 A1 1/2004 Kwon (22) Filed: Nov. 18, 2005 2004/0042971 A1 3/2004 Truong-Le et al. 2004/0042972 A1 3/2004 Truong-Le et al. (65) Prior Publication Data 2004.0043042 A1 3/2004 Johnson et al. 2004/OO57927 A1 3/2004 Warne et al. US 2007/O116729 A1 May 24, 2007 2004, OO63792 A1 4/2004 Khera et al.
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev
    Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM GADOCOLETICUM 280776-87-6 ABAFUNGIN 129639-79-8 ACIDUM LIDADRONICUM 63132-38-7 ABAMECTIN 65195-55-3 ACIDUM SALCAPROZICUM 183990-46-7 ABANOQUIL 90402-40-7 ACIDUM SALCLOBUZICUM 387825-03-8 ABAPERIDONUM 183849-43-6 ACIFRAN 72420-38-3 ABARELIX 183552-38-7 ACIPIMOX 51037-30-0 ABATACEPTUM 332348-12-6 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABETIMUSUM 167362-48-3 ACIVICIN 42228-92-2 ABIRATERONE 154229-19-3 ACLANTATE 39633-62-0 ABITESARTAN 137882-98-5 ACLARUBICIN 57576-44-0 ABLUKAST 96566-25-5 ACLATONIUM NAPADISILATE 55077-30-0 ABRINEURINUM 178535-93-8 ACODAZOLE 79152-85-5 ABUNIDAZOLE 91017-58-2 ACOLBIFENUM 182167-02-8 ACADESINE 2627-69-2 ACONIAZIDE 13410-86-1 ACAMPROSATE
    [Show full text]